CD36 inhibition to control obesity and insulin sensitivity
AssigneeCornell University - Cornell Center for Technology Enterprise & Commercialization (CCTEC)
InventorsSunghee Cho, Yi Bao, Eunhee Kim
Life of this patent
Estimating the term…
Abstract
The disclosure relates to the therapeutic utility of CD36 antagonists to reduce body weight, inhibit fat accumulation and especially visceral fat accumulation, improve insulin sensitivity, lower blood glucose levels, and treat and prevent metabolic syndrome, pre-diabetes and diabetes, and lower plasma cholesterol levels and decrease fat deposit in the liver. CD36 antagonists, including SAB or its metabolites, such as RA and DSS, are useful for these purposes.
Claims19
A method to reduce body weight in a subject in need thereof comprising administering to said subject an effective amount of a CD36 antagonist selected from the group consisting of salvianolic acid B (SAB), and sodium danshensu (DSS).
A method to inhibit fat accumulation in a subject in need thereof comprising administering to said subject an effective amount of a CD36 antagonist selected from the group consisting of salvianolic acid B (SAB), and sodium danshensu (DSS).
A method to increase insulin sensitivity or glucose tolerance in a subject in need thereof comprising administering to said subject an effective amount of a CD36 antagonist selected from the group consisting of salvianolic acid B (SAB), and sodium danshensu (DSS).
A method to treat or prevent diabetes or pre-diabetes in a subject in need thereof comprising administering to said subject an effective amount of a CD36 antagonist selected from the group consisting of salvianolic acid B (SAB), and sodium danshensu (DSS).
Dependencies are inferred from the claim text.